{"DataElement":{"publicId":"2794436","version":"1","preferredName":"Infectious Disorder Preventive Intervention Pharmacologic Substance Administered Type","preferredDefinition":"A description of the infection prophylaxis that was administered.","longName":"IFD_PVI_PHSB_ADM_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2794088","version":"1","preferredName":"Infectious Disorder Preventive Intervention Pharmacologic Substance Administered","preferredDefinition":"A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact. -- 2003_Therapeutic, nutritional, environmental, social and or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._An active natural, synthetic or semi-synthetic ingredient including endogenous body substance that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient (21 CFR 314.3(b))._The act of having given something (e.g., a medication or test).","longName":"ID_PI_PS_AD","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2794085","version":"1","preferredName":"Infection Preventive Intervention Pharmacologic Substance","preferredDefinition":"A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact. -- 2003:An attempt to prevent disease.:A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro.","longName":"C26726:C15843:C1909","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infectious Disorder","conceptCode":"C26726","definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59646E1E-F164-24AC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-16","modifiedBy":"ONEDATA","dateModified":"2008-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"59646E1E-F189-24AC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-16","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2794434","version":"1","preferredName":"Infectious Disorder Preventive Intervention Type","preferredDefinition":"A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact. -- 2003_Therapeutic, nutritional, environmental, social and or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._Something distinguishable as an identifiable class based on common qualities.","longName":"INF_DIS_PREV_INTV_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Nonabsorbable oral antibiotics","valueDescription":"Negation Absorbable  Oral Route of Administration Antibiotic","ValueMeaning":{"publicId":"2799757","version":"1","preferredName":"Negation Absorbable Oral Route of Administration Antibiotic","longName":"2799757v1.00","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction._Capable of being taken up or taken in._The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins._Substances naturally produced by microorganisms or their derivatives that selectively target microorganisms not humans. Antibiotics kill or inhibit the growth of microorganisms by targeting components of the microbial cell absent from human cells, including bacterial cell walls, cell membrane, and 30S or 50S ribosomal subunits. These substances are used in the treatment of bacterial and other microbial infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Absorbable","conceptCode":"C75520","definition":"Capable of being taken up or taken in.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibiotic","conceptCode":"C258","definition":"Substances naturally produced by microorganisms or their derivatives that selectively target microorganisms not humans. Antibiotics kill or inhibit the growth of microorganisms by targeting components of the microbial cell absent from human cells, including bacterial cell walls, cell membrane, and 30S or 50S ribosomal subunits. These substances are used in the treatment of bacterial and other microbial infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B94640F-EE11-66D8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-13","modifiedBy":"KUMMEROA","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B94640F-EE2A-66D8-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-13","modifiedBy":"NYCHM","dateModified":"2008-11-13","deletedIndicator":"No"},{"value":"Itraconazole","valueDescription":"Itraconazole","ValueMeaning":{"publicId":"2578206","version":"1","preferredName":"Itraconazole","longName":"2578206","preferredDefinition":"A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fugal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Itraconazole","conceptCode":"C1138","definition":"A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fungal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B94640F-EE36-66D8-E044-0003BA3F9857","beginDate":"2008-11-13","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-13","modifiedBy":"NYCHM","dateModified":"2008-11-13","deletedIndicator":"No"},{"value":"Acyclovir","valueDescription":"Acyclovir","ValueMeaning":{"publicId":"2575648","version":"1","preferredName":"Acyclovir","longName":"2575648","preferredDefinition":"A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses.  After conversion in vitro to the active metabolite acyclovir triphosphate, acyclovir competitively inhibits viral DNA polymerase, incorporates into and terminates the growing viral DNA chain, and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the thymidine kinase of HSV. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acyclovir","conceptCode":"C205","definition":"A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses of the herpesvirus family. After conversion in vivo to the active metabolite acyclovir triphosphate by viral thymidine kinase, acyclovir competitively inhibits viral DNA polymerase by incorporating into the growing viral DNA chain and terminating further polymerization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F48D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59DE68C5-AE87-583D-E044-0003BA3F9857","beginDate":"2008-10-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-22","modifiedBy":"COOPERM","dateModified":"2008-10-22","deletedIndicator":"No"},{"value":"Other pneumocystis prophylaxis","valueDescription":"Other Pneumocystis Pneumonia Preventive Intervention","ValueMeaning":{"publicId":"2794940","version":"1","preferredName":"Other Pneumocystis Pneumonia Preventive Intervention","longName":"2794940","preferredDefinition":"Not otherwise specified.: Pneumonia resulting from infection with Pneumocystis carinii, frequently seen in the immunologically compromised, such as persons with AIDS, or steroid-treated individuals, the elderly, or premature or debilitated babies during their first three months.  Patients may be only slightly febrile (or even afebrile), but are likely to be extremely weak, dyspneic, and cyanotic. This is a major cause of morbidity among patients with AIDS.: An attempt to prevent disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pneumocystis Pneumonia","conceptCode":"C3334","definition":"Pneumonia resulting from infection with Pneumocystis jirovecii, frequently seen in the immunologically compromised, such as persons with AIDS, or steroid-treated individuals, the elderly, or premature or debilitated babies during their first three months.  Patients may be only slightly febrile (or even afebrile), but are likely to be extremely weak, dyspneic, and cyanotic. This is a major cause of morbidity among patients with AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A00A568-2FCC-15CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A00A568-2FE5-15CD-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Other antiviral agent","valueDescription":"Other Antiviral Agent","ValueMeaning":{"publicId":"2794941","version":"1","preferredName":"Other Antiviral Agent","longName":"2794941","preferredDefinition":"Not otherwise specified.: Drugs used to treat infections caused by viruses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antiviral Agent","conceptCode":"C281","definition":"Any agent that can treat or prevent viral infections by interfering with the viral replication cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A00A568-2FF4-15CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A00A568-300D-15CD-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Other agent","valueDescription":"Other Pharmacologic Substance","ValueMeaning":{"publicId":"2775670","version":"1","preferredName":"Other Pharmacologic Substance","longName":"2775670","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FB5BE0-0144-7379-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"MAESKEB","dateModified":"2018-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A00A568-3022-15CD-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Micafungin","valueDescription":"Micafungin","ValueMeaning":{"publicId":"2794943","version":"1","preferredName":"Micafungin","longName":"2794943","preferredDefinition":"A semi-synthetic echinocandin derived from a natural product of the fungus Coleophama empedri with potent antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. Inhibition of this enzyme weakens of the cell wall, thereby leading to osmotic lysis and eventually, fungal cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Micafungin","conceptCode":"C1850","definition":"A semi-synthetic echinocandin derived from a natural product of the fungus Coleophama empedri with potent antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. Inhibition of this enzyme weakens of the cell wall, thereby leading to osmotic lysis and eventually, fungal cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A00A568-3058-15CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"5.5.17  Updated concept definition to synch with current NCIt. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A00A568-3071-15CD-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Foscarnet","valueDescription":"Foscarnet","ValueMeaning":{"publicId":"2794945","version":"1","preferredName":"Foscarnet","longName":"2794945","preferredDefinition":"A synthetic organic analogue of inorganic pyrophosphate with antiviral properties.  Foscarnet selectively blocks the pyrophosphate binding site of virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases.  Because this agent crosses the blood brain barrier, it may be used in the treatment of viral infections of the CNS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Foscarnet","conceptCode":"C71630","definition":"A synthetic organic analog of inorganic pyrophosphate with activity against several types of viruses, but primarily used for the treatment of cytomegalovirus retinitis. Foscarnet selectively blocks the pyrophosphate binding site of virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Because this agent crosses the blood brain barrier, it may be used in the treatment of viral infections of the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A00A568-3095-15CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A00A568-30AE-15CD-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Fluconazole","valueDescription":"Fluconazole","ValueMeaning":{"publicId":"2576944","version":"1","preferredName":"Fluconazole","longName":"2576944","preferredDefinition":"A synthetic triazole with antifungal activity. Fluconazole preferentially inhibits fungal cytochrome P-450 sterol C-14 alpha-demethylation, resulting in the accumulation of fungal 14 alpha-methyl sterols, the loss of normal fungal sterols, and fungistatic activity. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluconazole","conceptCode":"C500","definition":"A synthetic triazole with antifungal activity. Fluconazole preferentially inhibits fungal cytochrome P-450 sterol C-14 alpha-demethylation, resulting in the accumulation of fungal 14 alpha-methyl sterols, the loss of normal fungal sterols, and fungistatic activity. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F99D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A00A568-30BA-15CD-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Dapsone","valueDescription":"Dapsone","ValueMeaning":{"publicId":"2577850","version":"1","preferredName":"Dapsone","longName":"2577850","preferredDefinition":"A synthetic derivative of diamino-sulfone with anti-mycobacterial and anti-malarial properties.  A structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dapsone","conceptCode":"C415","definition":"A synthetic derivative of diamino-sulfone with anti-inflammatory and anti-bacterial properties. As a structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. Although the exact mechanism through which dapsone exerts its anti-inflammatory activity has yet to be fully elucidated, this agent interferes with the activation and oxidative damage of myeloperoxidase in neutrophils and inhibits the integrin-mediated adherence and chemotaxis of neutrophils. Dapsone's anti-inflammatory activities may contribute to the effects seen upon topical administration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD27-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A00A568-30C6-15CD-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Caspofungin","valueDescription":"Caspofungin","ValueMeaning":{"publicId":"2577795","version":"1","preferredName":"Caspofungin","longName":"2577795","preferredDefinition":"The acetate salt of an antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. Caspofungin inhibits 1,3-beta-glucan synthase, resulting in decreased synthesis of beta(1,3)-D-glucan (an essential component of the fungal cell wall), weakening of the fungal cell wall, and fungal cell wall rupture. This agent is active against Aspergillus and Candida species.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Caspofungin","conceptCode":"C28910","definition":"An antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. Caspofungin inhibits 1,3-beta-glucan synthase, resulting in decreased synthesis of beta(1,3)-D-glucan (an essential component of the fungal cell wall), weakening of the fungal cell wall, and fungal cell wall rupture. This agent is active against Aspergillus and Candida species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A00A568-30D2-15CD-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Voriconazole","valueDescription":"Voriconazole","ValueMeaning":{"publicId":"2575726","version":"1","preferredName":"Voriconazole","longName":"2575726","preferredDefinition":"A synthetic triazole with antifungal activity. Voriconazole selectively inhibits 14-alpha-lanosterol demethylation in fungi, preventing the production of ergosterol, an essential constituent of the fungal cell membrane, and resulting in fungal cell lysis. (NCI04).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Voriconazole","conceptCode":"C1707","definition":"A synthetic triazole with antifungal activity. Voriconazole selectively inhibits 14-alpha-lanosterol demethylation in fungi, preventing the production of ergosterol, an essential constituent of the fungal cell membrane, and resulting in fungal cell lysis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2017-05-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A01A143-EFD4-52D0-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Valacyclovir","valueDescription":"Valacyclovir","ValueMeaning":{"publicId":"2743501","version":"1","preferredName":"Valacyclovir","longName":"2743501","preferredDefinition":"The hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir. Orally administered, valacyclovir is rapidly converted to acyclovir which inhibits viral DNA replication after further conversion to the nucleotide analog acyclovir triphosphate by viral thymidine kinase, cellular guanyl cyclase, and a number of other cellular enzymes. Acyclovir triphosphate competitively inhibits viral DNA polymerase; incorporates into and terminates the growing viral DNA chain; and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against herpes simplex virus (HSV) compared with varicella-zoster virus (VZV) is due to its more efficient phosphorylation by HSV thymidine kinase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valacyclovir","conceptCode":"C28235","definition":"The hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir. Orally administered, valacyclovir is rapidly converted to acyclovir which inhibits viral DNA replication after further conversion to the nucleotide analog acyclovir triphosphate by viral thymidine kinase, cellular guanyl cyclase, and a number of other cellular enzymes. Acyclovir triphosphate competitively inhibits viral DNA polymerase; incorporates into and terminates the growing viral DNA chain; and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against herpes simplex virus (HSV) compared with varicella-zoster virus (VZV) is due to its more efficient phosphorylation by HSV thymidine kinase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3433CB-B6A5-3213-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"COOPERM","dateModified":"2018-03-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A01A143-EFFE-52D0-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Systemic antibacterial antibiotics","valueDescription":"Systemic Antibiotic","ValueMeaning":{"publicId":"2794971","version":"1","preferredName":"Systemic Antibiotic","longName":"2794971","preferredDefinition":"(sis-TEM-ik) Affecting the entire body.: (an-tih-by-AH-tik) A drug used to treat infections caused by bacteria and other microorganisms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic","conceptCode":"C13310","definition":"Affecting an entire system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibiotic","conceptCode":"C258","definition":"Substances naturally produced by microorganisms or their derivatives that selectively target microorganisms not humans. Antibiotics kill or inhibit the growth of microorganisms by targeting components of the microbial cell absent from human cells, including bacterial cell walls, cell membrane, and 30S or 50S ribosomal subunits. These substances are used in the treatment of bacterial and other microbial infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A01A143-F022-52D0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A01A143-F03B-52D0-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Ravuconazole","valueDescription":"Ravuconazole","ValueMeaning":{"publicId":"2794972","version":"1","preferredName":"Ravuconazole","longName":"2794972","preferredDefinition":"A triazole with antifungal activity. Ravuconazole inhibits 14a demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ravuconazole","conceptCode":"C38688","definition":"A triazole with antifungal activity. Ravuconazole inhibits 14a demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A01A143-F049-52D0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A01A143-F062-52D0-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Posaconazole","valueDescription":"Posaconazole","ValueMeaning":{"publicId":"2794973","version":"1","preferredName":"Posaconazole","longName":"2794973","preferredDefinition":"A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Posaconazole","conceptCode":"C61500","definition":"A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A01A143-F070-52D0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A01A143-F089-52D0-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Pentamidine IV","valueDescription":"Pentamidine Intravenous Route of Administration","ValueMeaning":{"publicId":"2794976","version":"1","preferredName":"Pentamidine Intravenous Route of Administration","longName":"2794976","preferredDefinition":"A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04): Administration within or into a vein or veins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentamidine","conceptCode":"C731","definition":"A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A01A143-F098-52D0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A01A143-F0B1-52D0-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Pentamidine inhaled","valueDescription":"Pentamidine Inhaler","ValueMeaning":{"publicId":"2794978","version":"1","preferredName":"Pentamidine Inhaler","longName":"2794978","preferredDefinition":"A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04): A device by means of which a medicinal product can be administered by inspiration through the nose or the mouth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentamidine","conceptCode":"C731","definition":"A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Inhaler","conceptCode":"C16738","definition":"A device by means of which a medicinal product can be administered by inspiration through the nose or the mouth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A01A143-F0C1-52D0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A01A143-F0DA-52D0-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Other systemic antifungal agent","valueDescription":"Other Systemic Antifungal Agent","ValueMeaning":{"publicId":"2794979","version":"1","preferredName":"Other Systemic Antifungal Agent","longName":"2794979","preferredDefinition":"Not otherwise specified.: (sis-TEM-ik) Affecting the entire body.: Drugs that treat infections caused by fungi.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Systemic","conceptCode":"C13310","definition":"Affecting an entire system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antifungal Agent","conceptCode":"C514","definition":"Substances that treat systemic or topical infections caused by fungi. Antifungal agents kill or inhibit the growth of fungi, by various mechanisms. These mechanisms include inhibition of fungal mitosis, impairing synthesis or binding to ergosterol, inhibition of RNA or DNA synthesis, and interfering with other fungal metabolic processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A01A143-F0EA-52D0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A01A143-F103-52D0-E044-0003BA3F9857","beginDate":"2008-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"COOPERM","dateModified":"2008-10-24","deletedIndicator":"No"},{"value":"Amphotericin (lipid formulation)","valueDescription":"Amphotericin B-Lipid Complex","ValueMeaning":{"publicId":"2576889","version":"1","preferredName":"Amphotericin B-Lipid Complex","longName":"2576889","preferredDefinition":"Consists of the macrolide antibiotic Amphotericin B complexed with dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol, formulated to provide lower toxicity with efficacy similar to the parent compound, Amphotericin B.  Amphotericin B binds to ergosterol altering cell membrane integrity with subsequent cell death. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposomal Amphotericin B","conceptCode":"C1566","definition":"A liposome-encapsulated formulation of the polyene antifungal antibiotic amphotericin B produced by the bacterium Streptomyces nodosus with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane, and alters cell membrane integrity, resulting in leakage of intracellular components and cell rupture. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells. Compared to amphotericin B alone, liposomal delivery of amphotericin B allows for a greater drug concentration in target tissues while decreasing systemic side effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F966-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7677ED4C-F1A7-A780-E040-BB89AD4307C4","beginDate":"2008-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-21","modifiedBy":"ONEDATA","dateModified":"2009-10-21","deletedIndicator":"No"},{"value":"Amphotericin (non-lipid formulation)","valueDescription":"Amphotericin B Deoxycholate","ValueMeaning":{"publicId":"2794946","version":"1","preferredName":"Amphotericin B Deoxycholate","longName":"2794946","preferredDefinition":"The deoxycholate salt of amphotericin B, a polyene antifungal antibiotic produced by Streptomyces nodosus, with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane, resulting in depolarization of the membrane; alterations in cell membrane permeability and leakage of important intracellular components; and cell rupture. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amphotericin B Deoxycholate","conceptCode":"C62201","definition":"The deoxycholate salt of amphotericin B, a polyene antifungal antibiotic produced by Streptomyces nodosus, with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane. This results in depolarization of the cell membrane, alterations in cell membrane permeability, leakage of important intracellular components, and cell rupture. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A00A568-30F5-15CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7677ED4C-F1BB-A780-E040-BB89AD4307C4","beginDate":"2008-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-21","modifiedBy":"ONEDATA","dateModified":"2009-10-21","deletedIndicator":"No"},{"value":"Atovaquone","valueDescription":"Atovoquone","ValueMeaning":{"publicId":"2575655","version":"1","preferredName":"Atovoquone","longName":"2575655","preferredDefinition":"A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atovaquone","conceptCode":"C28838","definition":"A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F494-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"CURTIST","dateModified":"2010-01-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7677ED4C-F1CF-A780-E040-BB89AD4307C4","beginDate":"2008-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-21","modifiedBy":"ONEDATA","dateModified":"2009-10-21","deletedIndicator":"No"},{"value":"Ganciclovir","valueDescription":"Ganciclovir","ValueMeaning":{"publicId":"2575684","version":"1","preferredName":"Ganciclovir","longName":"2575684","preferredDefinition":"A synthetic guanine derivative with antiviral activity.  As the active metabolite of ganciclovir, ganciclovir-5-triphosphate (ganciclovir-TP) appears to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganciclovir","conceptCode":"C517","definition":"A synthetic guanine derivative with antiviral activity.  As the active metabolite of ganciclovir, ganciclovir-5-triphosphate (ganciclovir-TP) appears to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7677ED4C-F1D9-A780-E040-BB89AD4307C4","beginDate":"2008-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-21","modifiedBy":"ONEDATA","dateModified":"2009-10-21","deletedIndicator":"No"},{"value":"Trimethoprim/sulfamethoxazole","valueDescription":"Trimethoprim-Sulfamethoxazole","ValueMeaning":{"publicId":"2577719","version":"1","preferredName":"Trimethoprim-Sulfamethoxazole","longName":"2577719","preferredDefinition":"A combination of two anti-infection drugs, sulfamethoxazole and trimethoprim. It is used to fight bacterial and protozoal infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimethoprim-Sulfamethoxazole","conceptCode":"C909","definition":"A synthetic combination of two antibacterial agents, trimethoprim and sulfamethoxazole. This synergistic combination, also known as Co-Trimoxazole, inhibits two sequential steps in the bacterial metabolism of folic acid. Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase; sulfamethoxazole is a sulfamide inhibitor of bacterial dihydrofolate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-17","modifiedBy":"ONEDATA","dateModified":"2006-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7677ED4C-F1ED-A780-E040-BB89AD4307C4","beginDate":"2008-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-21","modifiedBy":"ONEDATA","dateModified":"2009-10-21","deletedIndicator":"No"},{"value":"Valganciclovir","valueDescription":"Valganciclovir","ValueMeaning":{"publicId":"2575724","version":"1","preferredName":"Valganciclovir","longName":"2575724","preferredDefinition":"A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, viral DNA synthesis, and viral replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valganciclovir","conceptCode":"C2629","definition":"A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, viral DNA synthesis, and viral replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4D9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2018-03-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7677ED4C-F1F7-A780-E040-BB89AD4307C4","beginDate":"2008-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-21","modifiedBy":"ONEDATA","dateModified":"2009-10-21","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2794433","version":"1","preferredName":"Infection Preventive Intervention Type","preferredDefinition":"A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact. -- 2003:An attempt to prevent disease.:Type; a subdivision of a particular kind of thing.","longName":"C26726:C15843:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infectious Disorder","conceptCode":"C26726","definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59DE68C5-AE61-583D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-22","modifiedBy":"ONEDATA","dateModified":"2008-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"59DE68C5-AE72-583D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-22","modifiedBy":"NYCHM","dateModified":"2010-11-23","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964902","version":"1","longName":"2100r1: 100 Days Post-HSCT Data","context":"NHLBI"},{"publicId":"2964922","version":"1","longName":"2200r1: 6 Month to 2 Year Post-HSCT Data","context":"NHLBI"},{"publicId":"2964923","version":"1","longName":"2300r1: Greater Than 2 Years Post-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"MaterialName:name","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the agent types recei","type":"Preferred Question Text","description":"Specify the agent types received for infection prophylaxis:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2794436","type":"BRIDG Mapping Path","description":"PerformedProcedure > DefinedProcedure > Product > MaterialName.name  WHERE Product.typeCode = \"Pharmacologic Substance\" AND DefinedProcedure.reasonCode = \"Preventive Intervention\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"59DD988A-AE5D-049F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-22","modifiedBy":"ALEYR","dateModified":"2019-04-07","changeDescription":". System generated def displayed as alt def. AK 7/2/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}